Myostatin and activin blockade by engineered follistatin results in hypertrophy and improves dystrophic pathology in mdx mouse more than myostatin blockade alone

Por Andrea Iskenderian, Nan Liu, Qingwei Deng, Yan Huang, Chuan Shen, Kathleen Palmieri, Robert Crooker, Dianna Lundberg, Niksa Kastrapeli, Brian Pescatore, Alla Romashko, John Dumas, Robert Comeau, Angela Norton, Jing Pan, Haojing Rong, Katayoun Derakhchan, David E. Ehmann
Publicado em 2018-10-01